Brand Reference: Evista
| Metric | Verified Benchmark | Source |
|---|---|---|
| Raloxifene Hydrochloride RxNorm Concept ID | 72236 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $112.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $9.80 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $13.00 / mo | 18 Zero-PHI Verified Patient Logs |
Induces an estrogen-receptor conformation that recruits co-activators in osteoblasts (preserving vertebral bone mineral density and lowering LDL-C) while recruiting corepressors in mammary gland ductal tissue (blocking breast proliferation and regressing pubertal/TRT gynecomastia) with zero endometrial stimulation.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Raloxifene Hydrochloride (Evista, RxCUI 72236) at $0.2600 per unit, whereas walk-in chain pharmacies bill cash patients an average of $112.00 monthly—creating a 91% ($102.20/mo) wholesale arbitrage spread down to $9.80.
Systemic exposure to Raloxifene Hydrochloride reflects 2% absolute systemic after extensive presystemic glucuronidation absorption kinetics and intestinal ugt1a1, ugt1a8, ugt1a10 glucuronidation (zero cyp450); fecal excretion, sustaining receptor engagement across a 27.7 hours (via enterohepatic glucuronide recycling) half-life window (4–12 weeks mammary tissue regression; 12 months dexa gain response profile).
Dosing protocols (60 mg PO once daily) balance efficacy (85.60% patient satisfaction across 18 logs) against hot flashes (16% of reports), nocturnal calf cramps (9% of reports), with strict avoidance in prior dvt, pe, or retinal vein thrombosis; pregnancy.
Across 18 verified cash-pay logs, Raloxifene Hydrochloride achieves a 85.60% Worth-It rating with out-of-pocket spend averaging $13.00/mo versus $112.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 60 mg PO once daily for Raloxifene Hydrochloride; monthly out-of-pocket dropped to $8.62 compared with $112.00 retail.
Completed 10 weeks on Raloxifene Hydrochloride (60 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 60 mg PO once daily Raloxifene Hydrochloride sourced via Compounding ($11.37/mo cash pay without insurance prior authorization).